These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29714537)

  • 1. Sample Size for Biosimilar Trials: In Defense of Synthesis.
    Clark T; Jo SJ; Phillips A
    Ther Innov Regul Sci; 2018 May; 52(3):300-305. PubMed ID: 29714537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
    Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
    Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
    Cuellar S; McBride A; Medina P
    Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars: Rationale and current regulatory landscape.
    Olech E
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
    Moorkens E; Vulto AG; Huys I
    MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size calculations for the development of biosimilar products.
    Kang SH; Kim Y
    J Biopharm Stat; 2014; 24(6):1215-24. PubMed ID: 25032735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A consistency approach for evaluation of biosimilar products.
    Tsou HH; Chang WJ; Hwang WS; Lai YH
    J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer.
    Taïeb J; Aranda E; Raouf S; Dunn H; Arnold D
    Clin Colorectal Cancer; 2021 Mar; 20(1):42-51.e3. PubMed ID: 33243618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Milestones over the development of SB3, a trastuzumab biosimilar.
    Pivot X; Bondarenko I; Petit T; Curtit E
    Future Oncol; 2018 Nov; 14(27):2795-2803. PubMed ID: 29927335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
    Serna-Gallegos TR; La-Fargue CJ; Tewari KS
    Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional consistency and sample size considerations in a multiregional equivalence trial.
    Wu SC; Xu JF; Zhang XJ; Li ZW; He J
    Pharm Stat; 2020 Nov; 19(6):897-908. PubMed ID: 32716135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars.
    Barbier L; Declerck P; Simoens S; Neven P; Vulto AG; Huys I
    Br J Cancer; 2019 Jul; 121(3):199-210. PubMed ID: 31257362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On sample size requirement for analytical similarity assessment.
    Zhao Y; Chang YW; Chow SC
    J Biopharm Stat; 2018; 28(6):1143-1159. PubMed ID: 29513612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical development and trial design of biosimilar products: a Japanese perspective.
    Nagasaki M; Ando Y
    J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials for authorized biosimilars in the European Union: a systematic review.
    Mielke J; Jilma B; Koenig F; Jones B
    Br J Clin Pharmacol; 2016 Dec; 82(6):1444-1457. PubMed ID: 27580073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A descriptive analysis of real-world oncology biosimilar use in Japan.
    Roth JA; Rahshenas M; Nowacki G; Masurkar N; Shelbaya A; Tajima K; Dorman S; Ono C
    Future Oncol; 2024; 20(25):1837-1850. PubMed ID: 38864611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustainable Integration of US Food and Drug Administration-Approved Biosimilars: Pharmacy- Versus Physician-Driven Change.
    Waterhouse DM; Ward P; Drosick DR; Burdette C; Davies D; Mendenhall MA
    JCO Oncol Pract; 2023 Nov; 19(11):1053-1057. PubMed ID: 37738533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.